{"product_id":"onsior-robenacoxib-for-the-treatment-of-pain-and-inflammation-in-chronic-osteoarthritis-in-dogs","title":"ONSIOR \/\/ Robenacoxib \/\/ for the treatment of pain and inflammation in chronic osteoarthritis in dogs","description":"\u003ch2\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/h2\u003e\n\u003ch2\u003e\u003cspan\u003eONSIOR contains robenacoxib, for the treatment of pain and inflammation in chronic osteoarthritis in dogs. Onsior tablets are flavored and are voluntarily ingested by most dogs, they must not be broken or crushed.\u003c\/span\u003e\u003c\/h2\u003e\n\u003ch3\u003e\u003cspan\u003eRecommendations for proper administration:\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eAdminister orally. Do not take with food because clinical trials have shown greater effectiveness of robenacoxib when taken without food or at least 30 minutes before or after a meal.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan class=\"detailpiccontainer\"\u003e\u003cimg src=\"https:\/\/vet-magazin.ro\/companii\/stiri-industria-veterinara\/altius\/Onisor-40-mg-pentru-caini\/Onisor-40-mg-pentru-caini.jpg?v=1346512322\" title=\"Onisor 40 mg for dogs\" alt=\"Onisor 40 mg for dogs\"\u003e\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eDeclaration of active substances and other ingredient(s)\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eEach tablet contains the following amount of robenacoxib and is marked with \"NA\" on one side and the following symbols on the other side:\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003eRobenacoxib\/tablet Symbols\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003e5 mg AK\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003e10 mg BE\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003e20 mg CD\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003e40 mg BCK\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003eThe tablets are round, beige to brown in color and are indivisible. Onsior tablets are flavored and are voluntarily ingested by most dogs.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eIndication(s):\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eFor the treatment of pain and inflammation in chronic osteoarthritis in dogs.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eContraindications:\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eDo not use in dogs suffering from stomach ulcers or liver disease. Do not use together with other non-steroidal anti-inflammatory drugs (NSAIDs) or with corticosteroids, drugs commonly used in the treatment of pain, inflammation or allergies.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDo not use in case of hypersensitivity to robenacoxib or any of the ingredients of the tablets.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDo not use in pregnant or lactating bitches as the safety of robenacoxib has not been established during pregnancy and lactation or in dogs used for breeding purposes.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eAdverse reactions:\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eGastrointestinal adverse reactions were reported very frequently, but most cases were mild and resolved without treatment. Vomiting and soft faeces were very common, poor appetite and diarrhea were common, and cases of bloody faeces were rare. In dogs treated for up to 2 weeks, no increase in liver enzyme activity was observed.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHowever, with long-term treatment, increases in liver enzyme levels have been frequently reported. In most cases, liver enzyme activity either stabilized or decreased with continued treatment. There were no reported increases in liver enzyme levels associated with symptoms of anorexia, apathy or vomiting. If you notice serious effects or other effects that have not been mentioned in this leaflet, please inform your veterinarian. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe frequency of possible adverse effects is defined using the following convention: \u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003every common (affects more than 1 animal in 10)\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003ecommon (affects 1 to 10 animals in 100)\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003euncommon (affects 1 to 10 animals in 1,000)\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003erare (affects 1 to 10 animals in 10,000)\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003every rare (affects less than 1 animal in 10,000)\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003enot known (frequency cannot be estimated from the available data)\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cspan\u003eDosage for each species, route(s) of administration and mode of administration:\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eThe recommended dose of robenacoxib is 1 mg\/kg body weight with a range of 1-2 mg\/kg. Administer once daily according to the table below.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eBody weight Number of tablets by size (kg) 5 mg 10 mg 20 mg 40 mg\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003e2.5 to \u0026lt; 5 1 tablet\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003e5 to \u0026lt; 10 1 tablet\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003e10 to \u0026lt; 20 1 tablet\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003e20 to \u0026lt; 40 1 tablet\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003e40 to at 80 2 tablets\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe clinical effect appears within a week. Treatment should be discontinued after 10 days if no visible improvement occurs. In the case of long-term treatment, once the clinical effect is established, the dose of Onsior can be adjusted to the lowest effective individual dose reflecting the fact that the degree of pain and inflammation associated with chronic osteoarthritis can vary over time. Monitoring by a veterinarian is necessary in this case.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eSpecial warning(s)\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eThe safety of this veterinary medicinal product has not been established in dogs weighing less than 2.5 kg or less than 3 months of age.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn the case of long-term treatment, liver enzymes should be monitored at the beginning of treatment, for example after 2, 4 and 8 weeks.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThen, it is recommended to continue the constant monitoring, for example once every 3-6 months. Treatment should be discontinued if the level of liver enzymes increases significantly or if the animal shows symptoms such as anorexia, apathy or vomiting in combination with a high level of liver enzymes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAdministration to dogs with impaired cardiac, renal or hepatic function or to dogs that are dehydrated, have low circulating blood volume or low blood pressure may involve additional risks.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIf use cannot be avoided, these dogs require close monitoring. Use this veterinary medicinal product under the strict supervision of a veterinarian in dogs at risk of stomach ulcers or if the animal has previously shown intolerance to other NSAIDs. Onsior should not be administered with another NSAID.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePrevious treatment with other anti-inflammatory drugs may cause additional or increased adverse effects and, consequently, there should be a period of at least 24 hours without treatment with such substances before starting treatment with Onsior. However, during the treatment-free period, the pharmacokinetic properties of the previously used products must be taken into account.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eConcomitant treatment with drugs that act on renal flow, for example diuretics or angiotensin-converting enzyme inhibitors, should be clinically monitored. The simultaneous administration of potentially nephrotoxic drugs should be avoided because it can cause an increased risk of renal toxicity.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe simultaneous use of other active substances that have a high level of protein binding may compete with robenacoxib in terms of binding, and thus cause toxic effects.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eSpecial precautions for disposal of unused product or waste, as appropriate:\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eMedicines must not be thrown into waste water or household waste. Ask your veterinarian for information on how to dispose of medications that are no longer needed.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003ch2\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003ch2\u003e\u003cspan\u003eONSIOR contiene robenacoxib, per il trattamento del dolore e dell'infiammazione nell'osteoartrosi cronica nei cani. Le compresse di Onsior sono aromatizzate e vengono ingerite volontariamente dalla maggior parte dei cani, non devono essere rotte o frantumate.\u003c\/span\u003e\u003c\/h2\u003e\n\u003ch3\u003e\u003cspan\u003eRaccomandazioni per una corretta amministrazione:\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eSomministrare per via orale. Non assumere con il cibo perché studi clinici hanno dimostrato una maggiore efficacia del robenacoxib se assunto senza cibo o almeno 30 minuti prima o dopo un pasto.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan class=\"detailpiccontainer\"\u003e\u003cimg src=\"https:\/\/vet-magazin.ro\/companii\/stiri-industria-veterinara\/altius\/Onisor-40-mg-pentru-caini\/Onisor-40-mg-pentru-caini.jpg?v=1346512322\" title=\"Onisor 40 mg per cani\" alt=\"Onisor 40 mg per cani\"\u003e\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eDichiarazione dei principi attivi e degli altri ingredienti\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eOgni compressa contiene la seguente quantità di robenacoxib ed è contrassegnata con \"NA\" su un lato e con i seguenti simboli sull'altro lato:\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003eRobenacoxib\/compressa Simboli\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003e10 mg BE\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003e20 mg CD\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003e40 mg BCK\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003eLe compresse sono rotonde, di colore da beige a di colore bruno e sono indivisibili. Le compresse di Onsior sono aromatizzate e vengono ingerite volontariamente dalla maggior parte dei cani.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eIndicazione\/i:\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003ePer il trattamento del dolore e dell'infiammazione nell'osteoartrosi cronica nei cani.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eControindicazioni:\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eNon usare in cani affetti da ulcere allo stomaco o malattie del fegato. Non usare insieme ad altri farmaci antinfiammatori non steroidei (FANS) o con corticosteroidi, farmaci comunemente usati nel trattamento del dolore, dell'infiammazione o delle allergie.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eNon utilizzare in caso di ipersensibilità al robenacoxib o ad uno qualsiasi degli eccipienti delle compresse.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eNon usare in cagne in gravidanza o in allattamento poiché la sicurezza del robenacoxib non è stata stabilita durante la gravidanza e l'allattamento o in cani utilizzati a fini riproduttivi.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eReazioni avverse:\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eReazioni avverse gastrointestinali sono state segnalate molto frequentemente, ma nella maggior parte dei casi sono state lievi e si sono risolte senza trattamento. Vomito e feci molli erano molto comuni, scarso appetito e diarrea erano comuni e i casi di sangue nelle feci erano rari. Nei cani trattati fino a 2 settimane non è stato osservato alcun aumento dell’attività degli enzimi epatici.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eTuttavia, con il trattamento a lungo termine, sono stati frequentemente segnalati aumenti dei livelli degli enzimi epatici. Nella maggior parte dei casi, l’attività degli enzimi epatici si è stabilizzata o è diminuita con la prosecuzione del trattamento. Non sono stati segnalati aumenti dei livelli degli enzimi epatici associati a sintomi di anoressia, apatia o vomito. Se notate effetti gravi o altri effetti che non sono stati menzionati in questo foglio illustrativo, informate il vostro veterinario. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eLa frequenza dei possibili effetti avversi è definita utilizzando la seguente convenzione: \u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003emolto comune (colpisce più di 1 animale su 10)\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003ecomune (colpisce da 1 a 10 animali su 100)\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003enon comune (colpisce da 1 a 10 animali su 1.000)\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eraro (colpisce da 1 a 10 animali su 10.000)\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003emolto raro (colpisce meno di 1 animale su 10.000)\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003enon nota (la frequenza non può essere stimata sulla base dei dati disponibili)\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cspan\u003eDosaggio per ciascuna specie, via(e) di somministrazione e modalità di somministrazione:\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eLa dose raccomandata di robenacoxib è 1 mg\/kg di peso corporeo con un intervallo di 1-2 mg\/kg. Somministrare una volta al giorno secondo la tabella sottostante.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePeso corporeo Numero di compresse per dimensione (kg) 5 mg 10 mg 20 mg 40 mg\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003eda 2,5 a \u0026lt; 5 1 compressa\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003eda 5 a \u0026lt; 10 1 compressa\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003eda 10 a \u0026lt; 20 1 compressa\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003eda 20 a \u0026lt; 40 1 compressa\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003eda 40 a \u0026lt; 80 2 compresse\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eL'effetto clinico appare entro una settimana. Il trattamento deve essere interrotto dopo 10 giorni se non si riscontra alcun miglioramento visibile. Nel caso del trattamento a lungo termine, una volta stabilito l’effetto clinico, la dose di Onsior può essere aggiustata alla dose individuale efficace più bassa, tenendo conto del fatto che il grado di dolore e infiammazione associati all’osteoartrosi cronica può variare nel tempo. In questo caso è necessario il monitoraggio da parte di un veterinario.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eAvvertenze speciali\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eLa sicurezza di questo medicinale veterinario non è stata stabilita nei cani di peso inferiore a 2,5 kg o di età inferiore a 3 mesi.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn caso di trattamento a lungo termine, gli enzimi epatici devono essere monitorati all'inizio del trattamento, ad esempio dopo 2, 4 e 8 settimane.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSuccessivamente si consiglia di continuare il monitoraggio costante, ad esempio una volta ogni 3-6 mesi. Il trattamento deve essere interrotto se il livello degli enzimi epatici aumenta in modo significativo o se l'animale mostra sintomi quali anoressia, apatia o vomito in combinazione con un livello elevato degli enzimi epatici.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eLa somministrazione a cani con funzionalità cardiaca, renale o epatica compromessa o a cani disidratati, con basso volume sanguigno circolante o bassa pressione sanguigna può comportare rischi aggiuntivi.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSe l'uso non può essere evitato, questi cani richiedono un attento monitoraggio. Usare questo medicinale veterinario sotto lo stretto controllo di un veterinario nei cani a rischio di ulcera gastrica o se l'animale ha precedentemente mostrato intolleranza ad altri FANS. Onsior non deve essere somministrato con un altro FANS.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eUn precedente trattamento con altri farmaci antinfiammatori può causare ulteriori o maggiori effetti avversi e, di conseguenza, è necessario trascorrere un periodo di almeno 24 ore senza trattamento con tali sostanze prima di iniziare il trattamento con Onsior. Tuttavia, durante il periodo senza trattamento, è necessario tenere conto delle proprietà farmacocinetiche dei prodotti utilizzati in precedenza.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIl trattamento concomitante con farmaci che agiscono sul flusso renale, ad esempio diuretici o inibitori dell’enzima di conversione dell’angiotensina, deve essere monitorato clinicamente. La somministrazione contemporanea di farmaci potenzialmente nefrotossici deve essere evitata perché può causare un aumento del rischio di tossicità renale.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eL'uso simultaneo di altri principi attivi che hanno un elevato livello di legame proteico può competere con il robenacoxib in termini di legame e quindi causare effetti tossici.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003ePrecauzioni speciali per lo smaltimento del prodotto non utilizzato o dei rifiuti, a seconda dei casi:\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eI medicinali non devono essere gettati nelle acque reflue o nei rifiuti domestici. Chiedi al tuo veterinario informazioni su come smaltire i farmaci che non servono più.\u003c\/span\u003e\u003c\/p\u003e","brand":"Novartis","offers":[{"title":"10 MG X 30 tbl","offer_id":49594523386203,"sku":"","price":58.99,"currency_code":"EUR","in_stock":true},{"title":"20 MG X 30 tbl","offer_id":49594523418971,"sku":"","price":68.99,"currency_code":"EUR","in_stock":true},{"title":"40 MG X 30 tbl","offer_id":49594523451739,"sku":"","price":78.99,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0476\/3261\/3543\/files\/859290_big.jpg?v=1732874705","url":"https:\/\/www.petshopluna.com\/it\/products\/onsior-robenacoxib-for-the-treatment-of-pain-and-inflammation-in-chronic-osteoarthritis-in-dogs","provider":"Pet Shop Maya","version":"1.0","type":"link"}